Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04281472 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
A Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by argenx.
- Completed
- Registry status
- Phase 2
- Development phase
- 322
- Enrollment target
- 20
- Study locations
NCT04281472: Completed Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by argenx.
NCT04281472 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) that has completed, run by argenx. The registered enrollment target is 322 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (142% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04281472, a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), has completed, sponsored by argenx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 322 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
Conditions Studied
Interventions
- BIOLOGICAL efgartigimod PH20 SC in stage B
- OTHER placebo in stage B
Study Locations (20)
Florida
- Investigator site 0010072 - Boca Raton
- Investigator site 0010144 - Coral Springs
- Investigator site 0010023 - Jacksonville
- Investigator Site 0010068 - Maitland
- Investigator site 0010059 - Miami
- Investigator site 0010050 - Orlando
- Investigator site 0010172 - Ormond Beach
- Investigator site 0010006 - Tampa
California
- Investigator Site 0010032 - Carlsbad
- Investigator site 0010004 - Orange
- Investigator site 0010190 - Pomona
- Investigator site 0010160 - Rancho Mirage
- Investigator site 0010071 - San Francisco
Arizona
- Investigator site 0010013 - Phoenix
- Investigator site 0010055 - Scottsdale
Alabama
- Investigator site 0010065 - Birmingham
Colorado
- Investigator site 0010057 - Centennial
Connecticut
- Investigator site 0010026 - New Haven
Georgia
- Investigator site 0010125 - Augusta
Iowa
- Investigator site 0010011 - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2020-04-15 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 2 |
What the finished NCT04281472 record still lists
NCT04281472 is an interventional study that assigns participants to a tested intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (142% higher).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) appearing as the primary indexed condition, and to 2 interventions - of which efgartigimod PH20 SC in stage B is the first listed.
NCT04281472 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04281472 about?
NCT04281472 is a clinical study titled "A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)". This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
What is the current status of trial NCT04281472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 322 participants. The study started on 2020-04-15. Estimated completion is 2023-05-11.
What conditions does trial NCT04281472 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
What interventions are being tested in trial NCT04281472?
The interventions under investigation include: efgartigimod PH20 SC in stage B (BIOLOGICAL), placebo in stage B (OTHER).
Who is sponsoring clinical trial NCT04281472?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04281472 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04281472's enrollment target sits among peer trials
322 150th of 2000 higher than 1,850 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
ACTIVE NOT RECRUITING · Phase 2
-
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI